Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Romain Casey

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Neurology|July 16, 2025
Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple SclerosisCamille Robin, Fabien Rollot, Mathilde Lefort, et al.
Brain : a Journal of Neurology|February 14, 2026
Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosisFabien Rollot, Romain Casey, Anne Kerbrat, et al.
JAMA Neurology|July 1, 2024
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple SclerosisAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
Brain : a Journal of Neurology|September 18, 2020
Delay from treatment start to full effect of immunotherapies for multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
JAMA Neurology|March 25, 2024
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MSGuillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, et al.
JAMA Neurology|March 23, 2026
Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseMarine Boudot de la Motte, Antoine Gavoille, Caroline Papeix, et al.
Neurology|May 5, 2026
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple SclerosisAntoine Gavoille, Anne Kerbrat, Gilles Edan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Neurology|July 16, 2025
Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple SclerosisCamille Robin, Fabien Rollot, Mathilde Lefort, et al.
Brain : a Journal of Neurology|February 14, 2026
Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosisFabien Rollot, Romain Casey, Anne Kerbrat, et al.
JAMA Neurology|July 1, 2024
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple SclerosisAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
Brain : a Journal of Neurology|September 18, 2020
Delay from treatment start to full effect of immunotherapies for multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
JAMA Neurology|March 25, 2024
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MSGuillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, et al.
JAMA Neurology|March 23, 2026
Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseMarine Boudot de la Motte, Antoine Gavoille, Caroline Papeix, et al.
Neurology|May 5, 2026
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple SclerosisAntoine Gavoille, Anne Kerbrat, Gilles Edan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Pageof 7